Interim management statement19 Mar 2010 22:45
Source BioScience plc
(`Source BioScience', the `Company' or the `Group')
INTERIM MANAGEMENT STATEMENT
Growing demand for the Group's healthcare services underpins a 10% increase in
Q3 revenues and helps drive further strong cash generation as Source BioScience
builds on first half profitability
Source BioScience plc (LSE: SBS) the provider of diagnostic and screening
services to the healthcare community and genetic analysis and biomolecular
tools to the life science research and pharma biotech sectors, today provides
its Interim Management Statement (`IMS') as required by the UK Listing
Authority's Disclosure and Transparency Rules, relating to the period from 1
July 2009 to 17 November 2009.
Highlights:
* Revenue in Q3 increased by 10% compared with the same period last year
* Extended agreement with Cervical Screening Wales to supply liquid based
cytology equipment and reagents
* Expansion of laboratory capability at University College London with
introduction of new, enhanced technology platform for genotyping
* Significant growth opportunities across the Group as it benefits from
investment programme
* Further product and service portfolio enhancements expected
* Strong balance sheet with £6.8 million of cash underpins investment and
acquisition plans